102 entries found
Sort by: Latest |Relevance
28 Mar 2013 description
report PlusNews

BANGKOK, 28 March 2013 (PLUSNEWS) - As a UN high-level panel completes worldwide consultations [ http://www.post2015hlp.org/ ] to pick development goals for 2015 and beyond, PlusNews consulted experts to see how HIV/AIDS might fit into this new agenda.

05 Mar 2013 description
report PlusNews

JOHANNESBURG, 5 March 2013 (PLUSNEWS) - A three-year clinical trial involving over 5,000 women in East and Southern Africa has found that pre-exposure prophylaxis (PrEP) - whether a vaginal gel or an oral tablet - is not effective at preventing HIV infection in young, unmarried women.

16 Jan 2013 description
report PlusNews

JOHANNESBOURG, 16 janvier 2013 (PlusNews) - Le seul essai clinique de vaccin anti-VIH ayant obtenu un succès modéré a été réalisé il y a trois ans. Encore aujourd’hui toutefois, l’interprétation de ses résultats continue d’apporter de nouvelles informations au sujet du virus et ravive l’espoir d’un futur vaccin.

15 Jan 2013 description
report PlusNews

JOHANNESBURG, 15 January 2013 (PlusNews) - The only HIV vaccine trial to achieve moderate success took place four years ago, yet it continues to reveal new information about the virus and renew hopes for a future vaccine.

13 Dec 2012 description
report PlusNews

JOHANNESBURG, 13 December 2012 (PLUSNEWS) - If the world scales-up HIV treatment and prevention in the next two years, a critical tipping point - in which those on treatment outnumber those newly infected with the virus - could be reached, according to the global HIV prevention advocacy organization AVAC.

On the heels of AVAC's annual African Partners Forum, which was held in early December, IRIN/PlusNews breaks down the issues likely to top the HIV prevention agenda in the coming year.

05 Dec 2012 description
report PlusNews

JOHANNESBURG, 5 December 2012 (PLUSNEWS) - In early 2012, the UN World Health Organization (WHO) announced it could not conclusively determine whether hormonal contraceptive injections increased the risk of HIV transmission. Almost a year later, WHO is still struggling to communicate clear guidance for women using injectable contraceptives, who are largely in the dark about these concerns, say activists, even as scientists are developing a clinical trial that could finally offer answers.

30 Nov 2012 description
report PlusNews

JOHANNESBURG, 30 November 2012 (PLUSNEWS) - In its newly released "blueprint," [ http://www.pepfar.gov/documents/organization/201386.pdf ] the US President's Emergency Plan for AIDS Relief (PEPFAR) charts the next phase of the country's response to the HIV epidemic. In it, the largest funder of HIV efforts globally will focus on HIV prevention, new technologies, women and girls, and the most at-risk populations (MARPs).

30 Nov 2012 description
report PlusNews

NEW YORK CITY, 30 November 2012 (PLUSNEWS) - With whom did you last have sex? When? Where? How? At crowded food stalls and in dimly lit bars, Kelvin Parker carries out what HIV researchers call "sexual networking mapping".

Networking analysis involves getting intimate details from people who are most at risk of HIV infection to slow the spread of sexually transmitted infections.

29 Nov 2012 description
report PlusNews

NAIROBI, 29 November 2012 (PLUSNEWS) - The world is not on track to meet ambitious targets to significantly reduce sexual transmission of HIV, virtually eliminate mother-to-child HIV transmission and achieve universal access to treatment by 2015, according to a new report by global advocacy group ONE.

20 Nov 2012 description
report PlusNews

JOHANNESBURG, 20 November 2012 (PLUSNEWS) - After months of headhunting and interviews, the Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed Mark Dybul, former director of the US President's Emergency Plan for AIDS Relief (PEPFAR), as its new executive director. Dybul spoke to IRIN/PlusNews about the future of the Fund.

09 Nov 2012 description
report PlusNews

NAIROBI, 9 November 2012 (PLUSNEWS) - Private philanthropists in the European Union and the US spent some US$644 million on global HIV/AIDS programmes in 2011, a 5 percent increase from 2010, largely driven by funding from a small number of large donors, a new report has revealed.

21 Oct 2012 description
report PlusNews

BOSTON, 19 October 2012 (PlusNews) - A chemical engineer, a polymer physicist and a chemist gather for coffee - and not much happens. “We could have all the greatest ideas in the world to discuss over coffee, but without funding, it is not possible do to more than napkin sketches,” said Darrell Irvine, a material scientist at the US-based Massachusetts Institute of Technology (MIT) who, along with dozens of scientists, have received funding to break down silos of scientific disciplines to create an AIDS vaccine.

19 Oct 2012 description
report PlusNews

NAIROBI, 19 October 2012 (PLUSNEWS) - In humanitarian emergencies impoverished women may turn to sex work as a way of feeding themselves and their families; without the usual health services and given the often low education of those involved, sex is frequently unprotected, exposing them and their clients to sexually transmitted infections (STIs), including HIV.

17 Oct 2012 description
report PlusNews

NAIROBI, 17 October 2012 (PLUSNEWS) - - The UN Millennium Development Goal (MDG) target [ http://www.who.int/topics/millennium_development_goals/diseases/en/index.html ] of halting and reversing the tuberculosis (TB) epidemic by 2015 has been achieved, and the world is on track to meet the target [ http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf ] of reducing …

16 Oct 2012 description
report PlusNews

LONDON, 16 October 2012 (PLUSNEWS) - A research team at Oxford University in the UK is very close to determining the efficacy of their new tuberculosis (TB) vaccine. If current clinical trials are successful, it will be the first new TB vaccine in almost a century.

10 Oct 2012 description
report PlusNews

ADDIS ABABA, 10 October 2012 (PLUSNEWS) - African research to improve patient care and treatment is growing, but the dissemination of evidence-based approaches to healthcare lags behind, experts say.

At a five-day workshop on how to find the best available evidence for priority health issues in Africa, researchers called for the establishment of an Africa-based regional information hub to distribute scientific research on the continent's top killer diseases, including HIV, malaria and tuberculosis.

25 Sep 2012 description
report PlusNews

JOHANNESBURG, 25 September 2012 (PLUSNEWS) - The Global Fund to Fight AIDS, Tuberculosis and Malaria has released initial details on its new funding model, which will change the way countries apply for money. But as the Fund works to finalize the model before next year, civil society is criticizing the process for being untransparent and rushed.

04 Sep 2012 description
report PlusNews

JOHANNESBURG, 4 September 2012 (PlusNews) - The Global Fund to Fight AIDS, Tuberculosis (TB) and Malaria has announced that it has approved almost US$420 million to support essential services as part of its stop-gap Transitional Funding Mechanism (TFM), which was introduced late last year.

In November 2011, due to a lack of donations, the Global Fund was forced to cancel its Round 11 of funding. The TFM was introduced to prevent interruptions in essential prevention, treatment and care services.

30 Aug 2012 description
report PlusNews

JOHANNESBURG, 30 August 2012 (PLUSNEWS) - A new international study published in The Lancet finds that extensively drug resistant tuberculosis (XDR-TB) is more widespread than previously thought, and growing, leading researchers to reiterate calls for better infection control and new drugs.

22 Aug 2012 description
report PlusNews

NAIROBI, 22 August 2012 (PLUSNEWS) - Preachers who promise divine healing have often been blamed for turning desperate HIV-positive people against their life-prolonging antiretroviral (ARV) medication and risking their health, but recent research suggests that religious beliefs may not be a barrier to treatment after all.